# Traverse Biotech

Source: https://onco.cc/companies/traverse-biotech/  
OnCo record `traverse-biotech` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Traverse Biotech is a New York company that licenses immunotherapies already tested outside the United States and develops them further. Its lead product, TB-Bs1, is an antibody that links T cells to cancer cells carrying the protein ROR2.

## Summary

Traverse Biotech, of New York City, describes itself as an immunotherapy company that acquires products built on clinically validated platforms under a risk-sharing model with the licensing partner. Its pipeline page names TB-Bs1, a CD3 by ROR2 DuoBody bispecific antibody for ROR2-positive solid tumours, as its lead product, alongside an innate immunity programme, an antibody-drug conjugate in an undisclosed indication and an in situ immunotherapy platform. In fiscal year 2026 the National Cancer Institute funded its SBIR project on a uPAR-targeting antibody-drug conjugate for pancreatic adenocarcinoma (1R43CA309866-01, USD 399,896).

## Fields

- Kind: Company
- Last checked: 2026-11-04
- Also known as: TRAVERSE BIOTECH II INC; Traverse Biotechnology
- HQ: New York, NY
- Type: biotech
- Website: https://www.traversebiotech.com/

## Notes

- Read on traversebiotech.com (home and pipeline pages) and the NIH RePORTER record on 4 November 2026. The site does not say whether its undisclosed antibody-drug conjugate is the uPAR programme. No ROR2 target record exists in the corpus.

## Sources

- Official website: https://www.traversebiotech.com/
- Pipeline: https://www.traversebiotech.com/pipeline-4-1
- NIH RePORTER: 1R43CA309866-01: https://reporter.nih.gov/project-details/11309753

## Connected records

- cancers: [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/)
- fronts: [Antibody-Drug Conjugates](https://onco.cc/fronts/adcs/), [Immunotherapy](https://onco.cc/fronts/immunotherapy/)
- technologies: [Antibody-drug conjugate (ADC)](https://onco.cc/technologies/adc/), [T-cell engagers (bispecific)](https://onco.cc/technologies/t-cell-engager/)
- targets: [CD3](https://onco.cc/targets/cd3/)
- drugs: [TB-Bs1](https://onco.cc/drugs/tb-bs1/)

---
JSON: https://onco.cc/api/v1/entities/traverse-biotech.json